Xilio Therapeutics, Inc.

828 Winter Street, Suite 300

Waltham, MA 02451

 

November 16, 2022

 

VIA EDGAR SUBMISSION

 

U.S. Securities and Exchange Commission

Division of Corporation Finance, Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Attention: Christine Westbrook

 

Re:

Xilio Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-268264 Request for Acceleration

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Xilio Therapeutics, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-268264), so that it may become effective at 4:00 p.m., Eastern time, on November 18, 2022, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.

 

	Very truly yours,
	Xilio Therapeutics, Inc.
	By:	/s/ René Russo
		Name: René Russo
		Title: Chief Executive Officer